Theodore P Broten

Title: The Innovations of Theodore P. Broten

Introduction

Theodore P. Broten is a notable inventor based in Ambler, PA (US). He has made significant contributions to the field of medicine, particularly in the treatment of benign prostatic hyperplasia. With a total of 4 patents to his name, Broten's work has had a meaningful impact on patient care.

Latest Patents

One of his latest patents is focused on combination therapy for the treatment of benign prostatic hyperplasia. This invention relates to a combination therapy that includes an alpha-1a antagonist and an endothelin antagonist. More specifically, it utilizes a selective alpha-1a adrenergic receptor antagonist in conjunction with a subtype non-selective endothelin antagonist. This combination provides relief from lower urinary tract symptoms in patients suffering from symptomatic prostatism or benign prostatic hyperplasia. The therapy improves various symptoms, including increasing urine flow rate, decreasing residual urine volume, and enhancing overall obstructive and irritative symptoms.

Another patent involves phenoxyphenylacetic acid derivatives, showcasing Broten's diverse expertise in pharmaceutical innovations.

Career Highlights

Theodore P. Broten is currently associated with Merck & Company, Inc., a leading global healthcare company. His work at Merck has allowed him to focus on developing innovative solutions that address significant health challenges.

Collaborations

Throughout his career, Broten has collaborated with esteemed colleagues, including Scott William Bagley and Prasun K. Chakravarty. These collaborations have further enriched his research and development efforts.

Conclusion

Theodore P. Broten's contributions to medical innovation, particularly in the treatment of benign prostatic hyperplasia, highlight his role as a significant inventor in the pharmaceutical field. His patents reflect a commitment to improving patient outcomes and advancing medical science.